Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: investor (3)

Spartan Capital Annual Investor Conference
heltzeninvestor
CEO of eXoZymes to Present at Spartan Capital Securities’ Second Annual Investor ConferenceOctober 29, 2025
CEO of eXoZymes to Present at ThinkEquity’s Annual Investor Conference
heltzeninvestor
CEO of eXoZymes to Present at ThinkEquity’s Annual Investor ConferenceOctober 23, 2025
MDB Capital: eXoZymes & NCTx: The Breakthrough Opportunity with NCTx and Treating a Global Health Epidemic
heltzeninvestorpress clippingsvideo
MDB Capital: eXoZymes & NCTx: The Breakthrough Opportunity with NCTx and Treating a Global Health EpidemicSeptember 18, 2025
Transcript: Q2 2025 Earnings Call
investorvideo
Transcript: Q2 2025 Earnings CallAugust 13, 2025
eXoZymes provides second quarter 2025 update at 5PM EST today
press releaseinvestor
eXoZymes provides second quarter 2025 update at 5PM EST todayAugust 12, 2025
eXoZymes to host second quarter 2025 update on Tuesday August 12, 2025, at 5PM EST
press releaseinvestor
eXoZymes to host second quarter 2025 update on Tuesday August 12, 2025, at 5PM ESTAugust 7, 2025
eXoZymes details biomanufacturing breakthrough: 4 grams of NCT with over 99% purity
press releaseinvestornutraceuticalsvideoscience
eXoZymes details biomanufacturing breakthrough: 4 grams of NCT with over 99% purityJuly 29, 2025
eXoZymes biomanufacturing breakthrough: From concept to gram-scale NCT in only 5 months
press releaseinvestornutraceuticalsvideoscience
eXoZymes biomanufacturing breakthrough: From concept to gram-scale NCT in only 5 monthsJuly 22, 2025
Dr. Paul Opgenorth
press releaseinvestornutraceuticalsmedicinescience
eXoZymes selected as core industry partner in $9M NSF-funded initiative to advance modular cell-free biomanufacturingJune 26, 2025
Chris Marlett, MDB Capital
investorpress clippingsvideo
Slack Capital interview: Chris Marlett, Chairman of the BoardMay 22, 2025
Previous page
Page 3 of 8
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark